Pancreatic Cancer Research

ResearcherThe University of TokyoActive in the last 2 years

Naminatsu Takahara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1265-3100; OpenAlex author ID A5038774558. Sources: OpenAlex.

Their work

Papers
36 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
60
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 7 papers · 2014: 3 papers · 2015: 3 papers · 2016: 2 papers · 2017: 3 papers · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 5 papers · 2026: 2 papers

Papers 36

  1. Efficacy of steroid-omitting antiemetic therapy in patients with advanced pancreatic cancer receiving nano-liposomal irinotecan plus fluorouracil and leucovori… Co-author DOI 10.1007/s00520-026-10845-1↗
  2. Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futile pancreatectomy. Co-author DOI 10.1016/j.hpb.2025.12.021↗
  3. Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT d… Co-author DOI 10.1007/s00535-024-02173-0↗
  4. Factors associated with actionable gene aberrations in pancreatic cancer based on the C-CAT database. Co-author DOI 10.1007/s00535-025-02253-9↗
  5. Relationship of Intrapancreatic Fat Deposition With Pancreatic Cancer Differs According to Carcinoma Types. Co-author DOI 10.1053/j.gastro.2025.04.032↗
  6. Risk factors for pancreatic cancer in individuals with intraductal papillary mucinous neoplasms and no high-risk stigmata during up to 5 years of surveillance:… Co-author DOI 10.1136/gutjnl-2024-333259↗
  7. Endoscopic ultrasound-guided hepaticogastrostomy and endoscopic retrograde cholangiopancreatography-guided biliary drainage for distal malignant biliary obstru… Co-author DOI 10.5946/ce.2024.031↗
  8. Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospec… Co-author DOI 10.1007/s00520-023-07659-w↗
  9. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Last author DOI 10.1007/s10147-023-02317-x↗
  10. Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. First author DOI 10.1002/jhbp.1085↗
  11. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis. Co-author DOI 10.1007/s10637-020-00982-7↗
  12. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. Co-author DOI 10.1007/s10637-020-01022-0↗
  13. Screening Strategy of Pancreatic Cancer in Patients with Diabetes Mellitus. Co-author DOI 10.3390/diagnostics10080572↗
  14. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s10637-018-0691-9↗
  15. Diagnostic yield of the plasma free amino acid index for pancreatic cancer in patients with diabetes mellitus. Co-author DOI 10.1016/j.pan.2019.07.002↗
  16. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic … Co-author DOI 10.1007/s12032-018-1158-8↗
  17. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001079↗
  18. The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1097/mpa.0000000000000767↗
  19. Thromboembolisms in Advanced Pancreatic Cancer: A Retrospective Analysis of 475 Patients. Co-author DOI 10.1097/mpa.0000000000000889↗
  20. Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. Co-author DOI 10.1097/sla.0000000000001705↗
  21. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Co-author DOI 10.1007/s10637-016-0369-0↗
  22. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2016.05.016↗
  23. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Co-author DOI 10.1007/s00432-014-1873-2↗
  24. Pancreatic cancer with malignant ascites: clinical features and outcomes. Co-author DOI 10.1097/mpa.0000000000000290↗
  25. [IPMN and pancreatic cyst as high risk of pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.1474↗
  26. A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. Co-author DOI 10.1007/s00280-014-2563-0↗
  27. Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. Co-author DOI 10.1007/s12029-014-9603-1↗
  28. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Co-author DOI 10.1038/bjc.2014.131↗
  29. Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monoth… Co-author DOI 10.1007/s00280-012-1981-0↗
  30. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Co-author DOI 10.1007/s00280-013-2278-7↗
  31. A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer. Co-author DOI 10.1007/s00280-013-2313-8↗
  32. Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. Co-author DOI 10.1007/s00535-012-0622-z↗
  33. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Co-author DOI 10.1007/s10637-013-9972-5↗
  34. Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.03.013↗
  35. Risk for mortality from causes other than pancreatic cancer in patients with intraductal papillary mucinous neoplasm of the pancreas. Co-author DOI 10.1097/mpa.0b013e318270ea97↗
  36. Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer. Co-author DOI 10.1016/j.gie.2011.04.046↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yousuke Nakai · 32 shared papers, 2011–2025 · strength 2.53
  2. Kazunaga Ishigaki · 18 shared papers, 2015–2026 · strength 2.43
  3. Tsuyoshi Hamada · 25 shared papers, 2011–2025 · strength 2.14
  4. Mitsuhiro Fujishiro · 8 shared papers, 2023–2026 · strength 1.72
  5. Hiroyuki Isayama · 26 shared papers, 2011–2022 · strength 1.29
  6. Tatsunori Suzuki · 6 shared papers, 2023–2026 · strength 1.24
  7. Hirofumi Kogure · 25 shared papers, 2011–2021 · strength 1.22
  8. Kazuhiko Koike · 25 shared papers, 2011–2021 · strength 1.22
  9. Suguru Mizuno · 24 shared papers, 2011–2021 · strength 1.19
  10. Kei Saito · 15 shared papers, 2014–2023 · strength 1.11
  11. Hiroki Oyama · 6 shared papers, 2020–2025 · strength 1.03
  12. Minoru Tada · 22 shared papers, 2011–2019 · strength 0.92
  13. Koji Miyabayashi · 14 shared papers, 2013–2025 · strength 0.76
  14. Tomotaka Saito · 9 shared papers, 2015–2023 · strength 0.76
  15. Hideaki Ijichi · 16 shared papers, 2013–2021 · strength 0.69
  16. Yurie Tokito · 3 shared papers, 2025–2026 · strength 0.66
  17. Go Endo · 3 shared papers, 2025–2026 · strength 0.66
  18. Kiyoshi Hasegawa · 3 shared papers, 2018–2026 · strength 0.52
  19. Saburo Matsubara · 10 shared papers, 2011–2019 · strength 0.47
  20. Takashi Sasaki · 13 shared papers, 2013–2015 · strength 0.41
  21. Maxim S. Petrov · 2 shared papers, 2025 · strength 0.40
  22. Dai Mohri · 12 shared papers, 2011–2017 · strength 0.40
  23. Hidenori Kage · 2 shared papers, 2025 · strength 0.38
  24. Yukari Suzuki · 3 shared papers, 2020–2023 · strength 0.35
  25. Narikazu Boku · 1 shared paper, 2026 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.